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O
ne of themajor issues for the use of
nucleic acids as active therapeutics
for a broad range of cancers, in-
fectious disease and other disorders is the
safe and successful targeted delivery to
speciﬁc organs upon systemic administration.
We have reported an approach to generat-
ing a polymeric form of small interfer-
ing RNA (siRNA) that are eﬀectively self-
assembled into RNAi microsponge struc-
tures that can provide dense concentrations
of siRNA ultimately accessible within nano-
particles with orders of magnitude lower
concentrations of potentially toxic polycation1
anddescribed themechanismof self-assembly
and structure of these microsponges.2
Along with RNAi, similar delivery challenges
exist for other important forms of short
regulatory nucleic acids like antisense oligo-
nucleotides (ODN), which have a DNA back-
bone, and we seek to adapt these methods
accordingly. Furthermore, it is necessary to
introduce further modiﬁcation of the self-
assembled particles derived from these mi-
crosponges to achieve systems with appro-
priate biodistribution and plasma half-life
for meaningful delivery to targeted tissues.
Recently antisense therapy has been in-
troduced as one of the promising treatment
approaches for cancer because of its spe-
ciﬁc target selectivity in gene silencing,
an improved understanding of molecular
mechanisms in speciﬁc tumor types, and
the recent identiﬁcation of therapeutic
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ABSTRACT Antisense oligonucleotides can be employed as a potential
approach to eﬀectively treat cancer. However, the inherent instability and
ineﬃcient systemic delivery methods for antisense therapeutics remain major
challenges to their clinical application. Here, we present a polymerized oligo-
nucleotides (ODNs) that self-assemble during their formation through an enzy-
matic elongation method (rolling circle replication) to generate a composite
nucleic acid/magnesium pyrophosphate sponge-like microstructure, or DNA
microsponge, yielding high molecular weight nucleic acid product. In addition,
this densely packed ODN microsponge structure can be further condensed to generate polyelectrolyte complexes with a favorable size for cellular uptake by
displacing magnesium pyrophosphate crystals from the microsponge structure. Additional layers are applied to generate a blood-stable and
multifunctional nanoparticle via the layer-by-layer (LbL) assembly technique. By taking advantage of DNA nanotechnology and LbL assembly,
functionalized DNA nanostructures were utilized to provide extremely high numbers of repeated ODN copies for eﬃcient antisense therapy. Moreover, we
show that this formulation signiﬁcantly improves nucleic acid drug/carrier stability during in vivo biodistribution. These polymeric ODN systems can be
designed to serve as a potent means of delivering stable and large quantities of ODN therapeutics systemically for cancer treatment to tumor cells at
signiﬁcantly lower toxicity than traditional synthetic vectors, thus enabling a therapeutic window suitable for clinical translation.
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target genes that were traditionally recognized as
“undruggable”.37 When binding takes place, the
bound ODN/RNA hybrids serve as substrates for
enzyme-activateddegradation (e.g., RNaseH) or physical
blockage, resulting in the inhibition of translation of
their target sequences. Despite the powerful therapeu-
tic potential of ODNs, improved physicochemical prop-
erties of ODN backbones (e.g., speciﬁcity and stability),
and eﬃcient systemic delivery strategies are important
prerequisites for its clinical application in cancer. Sev-
eral useful chemical modiﬁcations of ODN backbones
have been reported to achieve improved resistance to
nuclease digestion and prolonged in vivo half-life.811
In addition, for eﬃcient antisense therapy to be clini-
cally realized, major challenges must be addressed to
achieve desirable therapeutic windows, such as ensur-
ing lower toxicity from delivery agents and the use of
lower quantities of packaging agents so as to provide
high amounts of active ODN drug loading per carrier
and improved stability in systemic circulation.12,13 In
addition, the uptake of nanocarriers via endocytic
pathways, its intracellular traﬃcking and eﬀective en-
dosomal escape, and the safe release of ODN drugs
from nanocarriers to functional targets in the cyto-
plasm and nucleus should also be considered.1418 In
order to deliver ODN therapeutics into a speciﬁc target
area, rational design of nanoparticles is required based
on particle size, surface chemistry, composition, shape,
chemical functionality, and mechanism of action.19
An important aspect of DNA nanotechnology is
the ability to engage molecular recognition and in-
trinsically deﬁne structural features with nanometer
precision,2023 which facilitates the employment of
useful strategies to construct functionalized DNA nano-
structures for their use in biomedical applications.24,25
Recently, several types of self-assembled functional
DNA nanostructures, composed of relatively short
oligonucleotides have been engineered for sensing,
bioimaging, and drug delivery.2630 In particular, roll-
ing circle replication (RCR) has been introduced as a
powerful method for nucleic acid synthesis.31 This
process of nucleic acid replication is particularly favor-
able for the production of long repeated strands of
nucleic acids in a stable form and at low cost. We have
used rolling circle transcription (RCT) to create self-
assembled RNAi microsponge structures1 and more
recently, the development of DNA hydrogels by using
rolling circle ampliﬁcation (RCA) has been reported.32
Both of these examples clearly demonstrate the power
of RCR in nucleic acid nanotechnology. Key to our
approach is the generation of concatenated or poly-
meric forms of nucleic acids that can be broken down
in cells by a native intracellular enzyme, Dicer, to short
oligonucleotide sequences relevant to gene silencing.
The resulting condensed polyplexes generated
from the microsponges can be directly modiﬁed using
the versatile approach of layer-by-layer (LbL)
assembly,33,34 for which key design parameters such
as layer components, layer number, and layer order,
make this platform a valuable option for tuning the
properties in therapeutic nanoparticle delivery
systems.3540 Delivery vehicles fabricated via LbL as-
sembly can carry multiple functional components,
precisely control the release of therapeutic drugs,
and facilitate improved biodistribution of the drug-
containing nanoparticle system. Various types of LbL
nanoparticle delivery systems have been reported to
facilitate cellular uptake, improve both drug and carrier
pharmacokinetics, and enhance molecular targeting
capability.4148
RESULTS AND DISCUSSION
As illustrated in Figure 1, we have developed a
concatenated DNA-based LbL-assembled nanoparticle
delivery platform. Using RCA, we initially generated
self-assembled composite DNA microsponge struc-
tures containing ODN's in the form of long single-
stranded oligonucleotide (ssDNA) polymers that each
contain several thousands of repeated ODN copies
complementary to a selected target sequence for
antisense therapy. The DNA microsponges were then
structurally disrupted by adding cationic polymers and
salts, which displace the magnesium pyrophosphate
crystals2 thatmake up the scaﬀold of themicrosponge;
this process leads to the formation of nanosized com-
plexes. Using this approach, we employed a long
polymeric ODN as the core region and applied addi-
tional outer-layer shells via LbL assembly. By rational
design and selection of biomaterials, we incorporated
multiple functional moieties in each layer compart-
ment. In addition, these LbL assembled polymeric ODN
structures demonstrated higher resistance to nuclease
digestion, prolonged in vivo half-lives, and controlled
release to overcome the inherent diﬃculties in their
delivery.
Antisense DNA Microsponge Particles. To generate anti-
sense particles that can self-assemble into organized
microstructures, we first designed and prepared a
linear ssDNA encoding complementary sequences of
ODN (see Supporting Information, Table S1). As a proof
of concept for biological function, we incorporated
DNA sequences complementary to antiluciferase ODN.
The linear ssDNA strand (91 bases) was then hybridized
with a primer ssDNA (22 bases), which was partially
complementary to both ends of the linear DNA, to form
a circular DNA. The nick inside the circular DNA was
connected by enzyme ligation with a T4 DNA ligase.
Gel electrophoresis was performed to demonstrate the
synthesis of circular DNA from the linear DNA structure
(see Supporting Information, Figure S1). A distinct
band shift between circular and linear DNA was ob-
served, indicating the successful assembly of circular
DNA. In the RCA process, this engineered circular DNA
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polymeric ODN sequences. The reaction was carried
out with high circular DNA concentrations (300 nM) in
the presence of DNA polymerase and allowed to
proceed for ∼24 h at room temperature. Spherulitic
sponge-like structures were formed consisting of a
magnesium pyrophosphate crystalline phase that acts
as a template for high loadings of polymeric ODN, for
which each polymer strand contains approximately
1700 tandem repeats of antiluciferase ODN. To prepare
more uniform particles, the reaction solution was
sonicated until the products were well dispersed. The
morphology and structure of the RCA product was
further studied using various microscopy techniques.
Scanning electron microscopy (SEM) images showed
that the ODN compositemicroparticles were uniformly
sized (∼2 μm), exhibited sponge-like porosity, and
were spheroidal in shape (Figure 2A,B). Because of
their morphology and biological function, we refer to
the resultant particles as oligodeoxynucleotide anti-
sense microsponge particles (ODN-MS). In addition,
transmission electron microscopy (TEM) images indi-
cated that this structure was hierarchical, composed of
multilayers of thin sheets that are further organized
into a branched spherulitic structure. In the higher
magnification TEM images, the two compartments
are clearly visualized, including the multilayers of thin
sheets and the highly branched structure inside the
particle (Figure 2C,D). Because of the presence of
magnesium pyrophosphate, the structure of the
ODN-MS was readily visualized without metal staining,
unlike typical DNA TEM imaging. Morphological
characteristics of the ODN-MS were further analyzed
using fluorescence and confocal microscopy to clearly
visualize the distribution of DNA in the microsponges.
In fluorescence microscopy analysis, the existence of
ssDNA in these particles was indicated by staining with
SYBR II, a DNA-specific dye, which exhibits green
fluorescence only when it binds with ssDNA. On the
basis of these observations, we confirmed that the
generated DNA product existed in ssDNA form in the
microsponge structure (see Supporting Information,
Figure S2). Interestingly, a ring-shaped distribution of
DNA was noticed in confocal microscopy images,
indicating the highly localized presence of ssDNA at
the edges of the particle surface. In this observation, we
used both SYBR II staining after the microsponge
structure formation and Cyanine 5-dUTP labeling dur-
ing the RCA reaction, which results in bright red and
green fluorescence, respectively (Figure 2E,F and Sup-
porting Information, Figure S2).
We have demonstrated that ODN-MS consists of
two diﬀerent components. Here, one pyrophosphate
anion (PPi) was produced from each nucleotide triphos-
phate during enzymatic nucleic acid polymerization
by RCA. The resulting PPi product was bound by
Mg2þ ions in the reaction buﬀer to form insoluble
magnesium pyrophosphate (Mg2PPi). To determine
the structure of the ODN-MS, scanning transmission
electron microscopy (STEM)-based energy dispersive
X-ray spectroscopy (EDX) mapping was carried out to
analyze the elemental composition of the ODN-MSs
(Supporting Information, Figure S3). On the basis of
Figure 1. Design of the multifunctional DNA-based layer-by-layer assembled nanoparticle. Schematic illustration of the
construction of multifunctional nanoparticle using three important strategies including the synthesis of antisense micro-
spongeparticles (ODN-MS), condensationprocess, and layer-by-layer assembly. A self-assembledmicrosponge-like structure
of DNA containing a large amount of periodic antisense oligodeoxynucleotide (ODN) strand in the form of a long polymeric
ssDNAwas synthesized using rolling circle ampliﬁcation (RCA) (Step 1). During condensation, ODN-MSwere totally disrupted
and then reconstructed into nanosized polyplexes by complexation with a selected polymer (Step 2). Next, keeping this
complexation as the core, additional outer layer shells were formed through layer-by-layer (LbL) assembly technique (Step 3).
Finally, these LbL-ODN nanoparticles (LbL-ODN-NPs) possessed multifunctionality due to the power of both functional DNA
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EDX, carbon (C) indicative of the presence of DNA, was
found to be distributed in both the inner and outer
particle regions. Similarly, magnesium (Mg), oxygen
(O), and phosphorus (P) from Mg2P2O7 were uniformly
distributed throughout the particle. Point analysis of
ODN-MSs using SEM-based EDX further supported the
presence of carbon, oxygen, magnesium, and phos-
phorus, respectively, indicating a mixture of DNA and
Mg2P2O7 within the ODN-MSs (Supporting Informa-
tion, Figure S4). To better understand the crystal-
lization of ODN-MSs during RCA, we used powder
X-ray diﬀraction (PXRD) to analyze their crystallinity
(Supporting Information, Figure S5). The diﬀraction
pattern matched well with the magnesium pyrophos-
phate phase Mg2P2O7 3 3.5H2O. Taken together with
the overall morphological and structural analysis of
ODN-MSs, these supporting results suggest that the
ODN-MSs generated during the RCA reaction are com-
posed of DNA/inorganic composite materials, includ-
ing densely packaged polymeric ODN and inorganic
magnesium pyrophosphate crystals, similar to our
observations for siRNA microsponges.2
We found that ODN strands from microsponges
generated using the RCA approach were an unusually
high molecular weight polymer structure. To conﬁrm
this notion, DNA microsponges were ﬁrst prepared
from circular DNA templates by RCA processes. These
microsponges were then treated with EDTA to chelate
Mg2þ. The subsequent DNA products were further
analyzed using SEM and gel electrophoresis to
Figure 2. Structural characterization of antisense microsponge particle. (A,B) SEM images of ODN-MS. Scale bars indicate
5 μm (A) and 1 μm (B), respectively. (C,D) TEM images of ODN-MS observed at low and higher magniﬁcation. Scale bars
indicate 500 nm (C) and 100 nm (D), respectively. (E,F) Confocalmicroscopy images ofODN-MS,whichwas functionalizedwith
Cy5-conjugated dUTP during the RCA process (red color). ODN-MS viewed at top point (E) and in themiddle section (F). Scale
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characterize the polymeric size of DNA. SEM images
indicated that the structure ofODN-MSwas completely
disrupted by the additional EDTA treatment (50 mM)
facilitating the direct comparison of polymeric struc-
tures from particles (Figure 3A). Gel image showed that
polymeric DNA was observed to run at a higher posi-
tion on the gel indicating an extremely large product
greater than 150 kb, corresponding to approximately
43millionDa (Figure 3B).49 Here, we conﬁrmed that the
generated DNA structures from the microsponge sys-
tem were very long polymeric structures, which corre-
spond to the number of ODN repeating units. On the
basis of the molecular weight analysis, several thou-
sand (∼1700) ODN repeats, each of which have the
speciﬁcally programmed target function of the ODN
sequence, could be generated during the RCA process
and incorporated into the ODN-MSs. In order to further
examine the size of the incorporatedDNApolymer into
microsponges during the DNA synthesis process, we
conducted a time course study of polymerized DNA
products during varied RCA reaction times. At each
reaction time point, ODN-MSs were isolated and DNA
polymer sizes were compared by gel electrophoresis
after disruption of the particles by EDTA. On the basis
of the results from gel electrophoresis, high molecular
weight DNA polymers were rapidly generated and
incorporated even in the initial stages of microsponge
formation (roughly equivalent to the 8 h RCA reaction)
(Supporting Information, Figure S6 and Lane 2, 4, 6);
these sizes are signiﬁcantly greater than those ob-
served for the siRNA systems.1,2 We performed a
ﬂuorescence-based measurement to quantify DNA
loading in the ODN-MSs (see Supporting Information).
DNA loading within the microsponge was approxi-
mately 12.5 ( 1.8 wt %; overall, we postulate that the
localized loading of DNA at the edge of the particle
may be due to the higher molecular weight of the
ssDNA.
We demonstrated that the long chain polymeric
ODN generated from the microsponge system exhib-
ited dramatically improved serum and nuclease sta-
bility, presumably due to the protective eﬀect of its
Figure 3. Characterization of polymeric DNA after extraction from antisense microsponge particle. (A) SEM images of ODN-
MSbefore and after EDTA treatment. Scale bars indicate 500nm. (B) Gel electrophoresis analysis to verify the size of polymeric
DNA disrupted by EDTA. Lane 12 indicate 1 and 5 kb DNA ladder, respectively. (C) Serum stability of polymeric DNA (top)
and short ssDNA (bottom) after a preassigned incubation time in a 50%serummedium. (D) Enzyme stability of polymericDNA
(top) and short ssDNA (bottom) after a preassigned incubation time in DNase (3 units/μL) at 37 C. (E) In vivo stability of
polymeric DNA and short ssDNA. Biodistribution of polymeric DNA (top) and short ssDNA (bottom) prior to injection followed
by 5 and 30min postinjection in NCr nude. Images are representative of a photographwith ﬂuorescent overlay (λex = 640 nm,
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polymerized form. We used an ssDNA quantiﬁcation
assay and gel electrophoresis to conﬁrm this ﬁnding by
evaluating the stability of the isolated polymeric ODN
structure from microsponge under the harsh condi-
tions of high serum (50%) and DNase (3 units/μL)
concentrations, respectively. Serum stability results
indicated that the polymeric ODN structure showed a
signiﬁcantly improved intrinsic stability compared to a
standard short ODN (∼22 bases). The amount of short
ODN decreased with increasing serum incubation time
(50% loss within 3 h). However, the polymeric ODN
structure was extremely well protected from serum
treatment during the 3 days of incubation (Figure 3C
and Supporting Information, Figure S5), and essentially
maintained its large size. Furthermore, the treatment of
short ODNs with DNase caused them to fully degrade,
leaving them undetectable by gel electrophoresis
(within ∼15 min). In contrast, although some damage
was observed under these harsh enzymatic conditions
and long incubation times (3 days), the polymeric
ODNs were signiﬁcantly more resistant to DNase en-
zyme degradation (Figure 3D and Supporting Informa-
tion, Figure S7). To further explore the systemic
delivery of the polymeric ODN, we performed an
in vivo pharmacokinetics study in NCr nude mice. Mice
were injected via the tail vein with Cy5 dye-labeled
polymeric or short ODNs and compared using whole-
animal and blood ﬂuorescence imaging to understand
the biodistribution and blood half-life and stability of
these systems. Rapid clearance for short ODN was
observed, as evident by a signiﬁcant bladder signal
(circled, 73% injected dose, based on bladder radiant
eﬃciency signal relative to the total integrated ﬂuo-
rescence recovered) present as early as 5 min, while
comparatively no bladder signal was evident for the
polymeric ODN up to 30 min, validating the avoidance
of renal ﬁltration by polymeric ODN due to size
(Figure 3E). Overall, the isolated polymeric ODN from
microsponges was signiﬁcantly protected from serum
and enzyme degradation, and reduced in vivo renal
clearance.
Polymeric ODN Packaging by Condensation. For achieving
desirable cellular and systemic ODNdelivery efficiency,
it is essential to obtain favorable sizes and appropriate
surface properties with compact ODN structures. In our
approach, the ODN-MS structures were disrupted and
the DNA product encapsulated in an additional pro-
cess (i.e., a condensation step) to control morphology,
charge, particle size, and surface structure. We further
investigated the mechanism of this polymeric DNA
packaging process during polycation condensation
starting from the DNA/inorganic composite micro-
sponge particles (ODN-MS). As we demonstrated pre-
viously, the microsponge can be easily broken down
from its original structure by sequestering Mg2þ using
chelating agents such as EDTA. In place of EDTA, we
used cationic polymers (e.g., poly-L-lysine: PLL) to act as
a condensing agent for DNA. ODN-MS has a highly
negative surface charge (37.14 ( 1.46 mV) due to
the presence of DNA and a relatively larger size
(∼1800 nm). The positively charged PLL binds readily
with ODN-MS by electrostatic interactions, forming
complex structures above a certain threshold concen-
tration with the composite structure. Following this
condensation step, ODN-MS transforms into a highly
compact sized structure facilitating polymeric ODN
drug loading. We realized that the major parameter
required for this condensation process is the initial
reaction concentration of the positively charged poly-
meric condensing agent in the presence of salts
(Supporting Information, Table S2). To find out the
optimal conditions for condensation, PLL concentra-
tionwas varied from 0.15mg/mL. Themorphology of
the condensed ODN-MS products was compared with
initial ODN-MSs using various microscopic techniques.
SEM images showed that ODN-MS microstructures
change their morphology during condensation de-
pending on the concentration of the polycation. At
intermediate concentrations of PLL (1.5 mg/mL), the
particles decreased in size (approximately 1 μm) and
became less porous than the initial ODN-MS structure
(Figure 4A,B); however, we observed the formation of
nanosized complexes as the PLL concentration was
increased (3 mg/mL, N/P = 0.5) (Figure 4C). We further
examined the condensed structures by carrying out
confocal microscopy with a dual-labeled fluorescence
system (polymeric ODN: green color and PLL: red color)
to observe the progression from microsponge to poly-
electrolyte complexation. Confocal microscopy images
were consistent with observations by SEM, which
indicated that the initial microsponge structure de-
creased in size and formed condensed structures
(Figure 4DG). There was no change in the ODN-MSs
at low PLL concentrations (below 0.4 mg/mL) in terms
of the particle size and surface charge. PLL appears
partially adsorbed to the ODN-MSs at intermediate
concentrations of PLL (between 0.40.8 mg/mL). The
shift of particle surface charge from 37.2 ( 1.5 mV
(ODN-MS) to þ4.6 ( 5.2 mV (ODN-MS/PLL) after
exposure to 0.8 mg/mL PLL concentration supports
the presence of PLL in the particles (Figure 4H,I).
Interestingly, at an intermediate concentration of PLL
(1.5 mg/mL), we observed that the ODN-MSs shrunk
from ∼2 μm to approximately 1 μm, and that PLL was
highly localized around the surface of ODN-MSs. This
was indicated by a red hue (corresponding to PLL) that
surrounds the green colored regions corresponding to
polymeric ODN. At certain thresholds of PLL concen-
tration (3 mg/mL), these structures form nanosized
polyplex structures composed of both PLL and poly-
meric ODNmolecules, which are observed as yellow in
color (corresponding to a merged color from both
polymeric ODN and PLL). At this PLL concentration,
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polyplexes following the reconfiguration of the ODN-
MSs. Following the condensation process, particles
were isolated from free polycation in solution by
dialysis. The ODN particles derived from the conden-
sing process were further investigated by dynamic
light scattering (DLS) and zeta (ζ)-potential analysis
(Figure 4H,I). As shown in Figure 4H, the size of complex
particles significantly decreased to 212.5 ( 15.6 nm
after the condensing process. The average size of
the original ODN-MSs was approximately 1800 (
196.1 nm. ζ-potential also helped in the verification
of the self-assembly of PLL with polymeric ODN. The
change of particle surface charge from37.2( 1.5 mV
(ODN-MS) to þ32.4 ( 1.6 mV (ODN-MS/PLL) indicated
the successful complexation of polymeric ODN with
PLL (Figure 4I). Our results also suggest that the outer
surfaces of the particle were saturated at 3 mg/mL of
PLL solutionbecause a significant increase inζ-potential
was not observed at higher concentrations of PLL.
We performed elemental analysis for further investiga-
tion of the polymeric ODN packaging process using
SEM-based EDX. Large differences between the rela-
tive amounts of O, Mg, and P were observed after
condensation along with dramatically increased rela-
tive amounts of C and N, which suggests the success-
ful release of magnesium pyrophosphate and the
incorporation of polymer (PLL) during condensation
(Supporting Information, Figure S4). Here O, Mg, and P
represent the presence of magnesium pyrophosphate
(Mg2P2O7 3 3.5H2O). In addition, both C and N indicate
the presence of the polymer-based condensing agent
(e.g., PLL). Further characterization of DNA packaging
before and after condensation was carried out using
powder XRD (PXRD). Specifically, the diffraction pat-
tern of the ODN-MSs after condensation did not in-
dicate the presence ofmagnesiumpyrophosphate crys-
tals in the particle (Supporting Information, Figure S5);
instead we observed a large broad peak consistent
with amorphous polymer. These results demonstrate
that PLL is capable of triggering the release of magne-
sium pyrophosphate from the ODN-MSs during con-
densation with the DNA product.
Overall, we found that the ODN-MS rearranges to
form smaller nanoparticle complexes at certain thresh-
old concentrations of polycation during condensation.
This was attributed to electrostatic interactions and
physical agitation alongwith the release ofmagnesium
pyrophosphate crystals. In conventional ODN com-
plexation approaches with polymers or lipids, the
amount of ODN per particle is very limited due to the
low surface charge and relative rigidity of short ODNs,
making their encapsulation especially challenging.
Figure 4. Characterization of polymeric DNA packaging by condensing process (AC) SEM images of ODN-MS before
condensingprocess (A) and after condensationwith varying concentrations of PLL (B,C). Scale bars indicate 1 μm. SEM images
show the reduced size of condensed nanoparticles with changed morphology. (DG) Confocal microscopy images of ODN-
MS after condensation with varying concentrations of PLL. Dual labeling was applied in this observation. PLL was
functionalized with Cy5 (red color) and DNA was stained with SYBR II, ssDNA speciﬁc dyes (green color). Magniﬁcation
was 60, and scale bars indicate 5 μm. (H) Size of ODN-MS/PLL at varied concentrations of condensing polymer. (I) ζ Potential
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In contrast, this approach uses a unique nucleic acid
packaging process, generating highly stabilized and
densely packed complexes due to the physicochemical
properties of the structured microsponge such as a
high localized surface charge density, and large surface
area presenting localized concentrations of ODN with
the improved condensation energetics and thermo-
dynamic driving forces of polymeric ODN compared to
rigid short ODN structures.50 We believe that this pro-
cess also allows a large amount of ODN encapsulation
due to the localization of the negatively charged poly-
meric DNA on the microsponge surfaces, which facili-
tates polycation complexation of nucleic acids at higher
concentrations relative to solution complexation.51
Properties of Layer-by-Layer Assembled Antisense DNA Micro-
sponge Particles. By first layering with PLL to condense
the polymeric antisense DNA, we can achieve a favor-
able size for cellular uptake, while maintaining a highly
concentrated polymeric ODN nanoparticle core for
enhanced drug delivery. Additional functional moi-
eties can be incorporated onto these structures via
LbL assembly to create an outer shell around the core,
including the incorporation of polyions that provide
the appropriate charge and hydration to achieve desir-
able biodistribution, and the introduction of targeting
moieties. In order to use the power of DNA as a generic
layering material in an LbL system, we used a short
length of synthetic ssDNA (30 bases) for the second
layer. Because of the high positive charge density of
the PLL/ODN core nanoparticles, a negatively charged
short ssDNA structure was readily adsorbed onto the
particles through electrostatic interaction. The result-
ing DNA-layered PLL/ODN particle (referred to as ODN-
MS/PLL/DNA) was then assembled again with linear
polyethylenimine (PEI), which is an effective endoso-
mal escape agent,52 as the third layer (referred to as
ODN-MS/PLL/DNA/PEI). The particle surface charge
(ζ-potential) and hydrodynamic size (DLS) of LbL-ODN
particles were characterized. The particle surface
charge was inverted during each layering step, indicat-
ing that the additional layer was constructed in a
stepwise fashion followed by alternating electrostatic
interactions. Initially, the ODN-MSs were layered at
3 mg/mL PLL, resulting in a positive surface charge
(þ32.4 ( 1.6 mV). These positively charged particles
were used for in vitro studies in which the charge
facilitates cell entry; whereas, in vivo experiments used
a final neutral PEG outer layer for bloodstream stability
and to create a stable stealth layer. The assembly of
short ssDNA strands onto the PLL/ODN particle was
successfully achieved by electrostatic adsorption, re-
sulting in a shift in ζ-potential to 23.0 ( 1.4 mV
(Figure 5A). Similarly, a positive ζ- potential from the
ODN-MS/PLL/DNA/PEI verified PEI self-assembly onto
the ODN-MS/PLL/DNA particles (Figure 5A). The size of
the ODN-MS/PLL/DNA/PEI particles was 223 ( 8.6 nm
in diameter following deposition of three layers onto
theODN-MSs (Figure 5B). On the basis of their sizes and
structures, we termed these nanoscale and polymer-
layered particles as LbL-ODN nanoparticles (LbL-ODN-
NPs). These LbL-ODN-NPswere further examined using
SEM and TEM. Images of ODN-MS/PLL/DNA/PEI also
show well dispersed particles with a diameter of
∼200 nm, which is compatible with the DLS results
(Figure 5CE). In comparison to earlier LbL-based DNA
encapsulation papers53,54 we find that (1) the ODN-MS
system can incorporate a polymeric form of functional
DNA (extremely large amounts of functional ODN unit
Figure 5. Properties of layer-by-layer assembled antisense microsponge particles. (A) ζ Potential of ODN-MS, ODN-MS/PLL,
ODN-MS/PLL/DNA, and ODN-MS/PLL/DNA/PEI. (B) Size of ODN-MS, ODN-MS/PLL, ODN-MS/PLL/DNA, and ODN-MS/PLL/DNA/
PEI. (C,D) SEM images of ODN-MS (C) and ODN-MS/PLL/DNA/PEI (D). Scale bars indicate 5 and 0.5 μm, respectively. (E) TEM
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per molecules) rather than just plasmid DNA, (2) im-
prove therapeutic nucleic acid loading efficiencies,
(3) can be adapted to undergo particle size changes
frommicro- to nanometer in scale during condensation
for favorable biological applications (e.g., drug delivery).
Intracellular and In Vivo Delivery of Layer-by-Layer Assembled
Antisense DNA Microsponge Particles. In the next step, we
analyzed the biological functions of LbL-ODN-NPs in
terms of intracellular delivery and polymeric ODN drug
delivery efficiency. To evaluate the genetic function of
polymeric ODN, we performed in vitro investigation of
the cellular uptake, knockdown efficiency, and cell
viability. In order to investigate the efficacy of poly-
meric ODN delivery in vitro, we prepared various types
of Cy5-labeled LbL-ODN-NPs by varying multilayer
number and corresponding surface charge. The syn-
thesized nanoparticles were transfected into cancer
cells (e.g., SKOV3) to observe the extent of cellular
uptake. Confocal microscopy results indicated that
LbL-ODN-NPs were successfully delivered into the cells
(3 h, complete medium) (Figure 6A). Moreover, cellular
uptake of ODN-MS/PLL/DNA/PEI particles in SKOV3
cells was qualitatively greater than that of the uncon-
densed ODN-MS, suggesting that their larger size and
net negative surface charge inhibits efficient transfec-
tion. Cellular uptake of ODN-MS/PLL/DNA/PEI particles
was attributed to ATP-mediated endocytosis because
very low fluorescence signal was observed within the
cells following incubation at 4 C. We further investi-
gated the cellular uptake of LbL-ODN-NPs by measur-
ing fluorescence intensity of dye-labeled particles
using flow cytometry (FACS) (Figure 6B). Similar trends
in cellular uptake were observed from FACS, validating
the confocal microscopy observations. Particles with a
positively charged outer surface layer (both ODN-MS/
PLL/DNA/PEI and ODN-MS/PLL) exhibited greater cel-
lular uptake, as anticipated, due to charge interactions
and nonspecific cell uptake. Moreover, these architec-
tures formed stable structures after four successive
layers (ODN-MS/PLL/DNA/PEI) and exhibited signifi-
cant uptake because of the intrinsic polycationic prop-
erties of PEI (Supporting Information, Figure S8). These
results suggest that employment of appropriate layer
numbers and selection of biomaterials play a key role
in LbL-ODN-NP cellular delivery. We also performed in
vitro gene knockdown to examine the therapeutic
efficiency of LbL-ODN-NPs (e.g., ODN-MS/PLL/DNA/
PEI). As a proof of concept, we chose firefly luciferase
as a genetic target of interest. Measurement of the
luciferase intensity after transfection indicated a sub-
stantial inhibition of gene expression (45.7( 6.8%) due
to the silencing effect of polymeric ODN fromODN-MS/
PLL/DNA/PEI (Figure 6C). Compared to conventional
lipid-based transfection strategies (e.g., lipofectamine),
Figure 6. Intracellular and in vivo delivery of layer-by-layer assembled antisense DNAmicrosponge particles. (A) Intracellular
delivery of layer-by-layer assembled antisense microsponge particles. Confocal microscopy image of cancer cells (e.g.,
SKOV3) treated with LbL-ODN-NPs. Nanoparticles were labeled red with Cy5. The actin cytoskeleton was stained green with
phalloidin, and the nucleus was stained blue with DAPI. Scale bars are 10 μm. (B) Cellular uptake study of LbL-ODN-NPs in
cancer cells (e.g., SKOV3) by using ﬂow cytometry analysis. (C) The knockdown eﬃciency of target gene expression for ﬁreﬂy
luciferase regulation using LbL-ODN-NPs was examined as a function of concentration in vitro. (D) Pharmacokinetics of
nanoparticle clearance from IV-administered BALB/c mice with various LbL-ODN-NPs formulations ﬁt with a 2-phase decay
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knockdown from polymeric ODN showed ∼50 fold
improved efficiency relative to knockdown from ODN
with lipofectamine in terms of the ODN concentration
from ODN-treated cells. Cell viability after treatment
with ODN-MS/PLL/DNA/PEI was also measured by the
MTT assay, indicating low toxicity particles (Supporting
Information, Figure S9). We expect that polymeric ODN
delivery after LbL assembly will result in improved
therapy due to augmented nuclease stability, high
drug loading, efficient delivery, and low cytotoxicity.
Because of the rapid clearance of short ODN with a
short plasma half-life in vivo (less than ∼5 min), it is
highly important to establish improved in vivo stability
of ODN. Assessment of LbL as ameans to stabilize ODN
was performed by ﬂuorescent modiﬁcation of the
polycationic component (PLL) of the ﬁlm with a near-
infrared dye (Cy5.5) to generate dye-labeled LbL-ODN-
NPs, speciﬁcally ODN-MS/PLL-Cy5.5/DNA (2L) and
ODN-MS/PLL-Cy5.5/DNA/PEI/DNA (4L) nanoparticles
were constructed to examine the biodistribution of
particles with net negative charge based on the non-
speciﬁc synthetic DNA outer layer. For a more general
outer stealth layer using a well-reported neutral pro-
tective hydrophilic polymer in circulation, polyethyl-
ene glycol (PEG)55 was also incorporated in the ﬁnal
layer of LbL-ODN-NPs using a block copolymer with a
negative charged polymer and PEG (e.g., PEG-b-poly-L-
glutamic acid), referred to ODN-MS/PLL/DNA/PEI/PEG
(PEG). The biological performance of these systems
was compared in immune-proﬁcient BALB/c mice by
whole-animal ﬂuorescence imaging up to 48 h after IV
injection. As shown in Figure 3E, the structure of the
ODN alone was not suitable for in vivo drug delivery
due to the rapid clearance of this therapeutic. The
ODN-MS/PLL/DNA/PEI/DNA (4L) showed improved
biological performance relative to nanoparticles with
ODN-MS/PLL/DNA (2L) (Figure 6D and Supporting
Information, Figure S10). The ODN-MS/PLL/DNA/PEI/
PEG (PEG) nanoparticles also showed longer blood
circulation persistence with additional layering and
steric stabilization by PEG. Both the 4L and PEG con-
structs from this study were observed to be good
packaging systems for the polymeric ODN construct.
The results from in vivo ﬂuorescence recovery from
live-animal bleeds for blood circulation determina-
tion were further substantiated by tissue necropsy
(Supporting Information, Figure S10). Reduced renal
clearance was also observed with additional outer
layers (4L and PEG) implying the protective eﬀect of
the polymeric ODNmolecule cores due to the presence
of additional layers for extended circulation proﬁles.
Moreover these LbL-ODN-NPs showed a signiﬁcantly
prolonged and a broad range of controlled plasma
half-life in comparison to the currently used chemically
modiﬁed ODNs (e.g., the phosphorothioate (PS) lin-
kages in ODNs and the 20-O-methoxyethyl (MOE)
modiﬁed ODNs: less than 24 h compared to the
LbL-ODN-NPs 1925 h.3,56 In addition diﬀerent biodis-
tribution tendencies were obtained when compared
to the layered particles (Supporting Information,
Figure S10). We monitored the accumulation of the
engineered LbL-ODN-NPs inﬁvemajor organsby ex vivo
ﬂuorescence images at 24 h postinjection. The kidney
and liver were the primary organs of LbL-ODN-NPs
accumulation, however these compounds were also
distributed widely throughout the body. A certain level
of quantiﬁed ﬂuorescence signal from liver (∼22% ID/g)
was also detected within 24 h after LbL-ODN-NPs
systemic injection. This system compares similarly to
other reported nanoparticle systems with regard to
biodistribution and liver accumulation, including LbL
particles43,45 and pegylated liposome.57 Furthermore,
we emphasize that the DNA-based LbL-assembled
nanoparticle system (e.g., ODN-MS/PLL/DNA/PEI/DNA)
can be used in systemic delivery applications because
of its improved stability for longer periods of time
in vivo. Taken together, these improved biological
performances were attributed to the selection of ap-
propriate biomaterial candidates for tuning the surface
properties of the ODN nanoparticles, the stability of
inherent polymeric ODN, and the use of stabilizing LbL
architectures. Further modiﬁcation of the outer layers
can be achieved for speciﬁc tumor types using target-
ing moieties, as we have shown with other LbL nano-
particle systems.43,45,58,59
CONCLUSIONS
Our work on DNA-based LbL-ODN nanoparticle
systems is unique in terms of the use of polymeric
DNA as a therapeutic agent, LbL assembly, and func-
tionalization. This study successfully demonstrates the
synthesis of DNA-based microsponge particles that
contain highly concentrated polymeric nucleic acids
(e.g., ODN) and magnesium pyrophosphate crystals.
Furthermore, this report demonstrates speciﬁc con-
densation processes to package large amounts of
polymeric ODN within a nanoparticle core. Unlike
conventional ODN-loading process with lipids and
polymers, ODN-MSs require an additional procedure
to disrupt their inorganic structure and reassemble into
nanosized polycation complexes. This approach allows
the encapsulation of polymeric DNA-based molecules
such asODN for therapeutic purposes for eﬃcient drug
loading and delivery. Moreover, by employing LbL
assembly onto the condensed ODN-MSs, ﬁne-tuning
of their multifunctional properties can be achieved for
imaging, and tunable surface charge, resulting in an
improved intracellular uptake and therapeutic eﬃcacy
with a negligible cytotoxicity. This platform possesses
multifunctionality because of the selection of appro-
priate biomaterials, which include PLL, DNA, PEI, and
PEG. In addition, this electrostatically assembled multi-
layered nucleic acid delivery system provides en-
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surface chemistry and the number of particle layers,
allowing for eﬃcient systemic delivery. Because the
layering of LbL-ODN-NPs system can bemodularly and
precisely controlled, further modiﬁcation of the parti-
clesmultifunctionality is possible for other applications
by rationally combining biofunctional polyelectrolytes
along with DNA. Our group is extensively investigating
further systemic applications in cancer therapy and
their eﬃcacy toward speciﬁc diseases and tumor tar-
gets. This DNA-based modular platform approach
oﬀers the promise of a potent delivery method for
nucleic acid therapeutics for cancer treatment.
METHODS
Circular DNA Template Design. The circularized ssDNA was used
as a template for RCA. To prepare oligonucleotide sequences,
linear ssDNA (91 bases) was designed to be comprised of a
sequence complementary to the antisense sequence (red color
in Figure S1, Supporting Information, indicates a region for
firefly luciferase targeting), a sequence complementary to the
primer ssDNA sequence (blue color in Figure S1 indicates two
hybridization regionswith primer ssDNA), and a linker sequence
(black color in Figure S1). The primer ssDNA contains two
hybridization regions with linear ssDNA (one portion with
16 bases at the 50 end and another portion with 6 bases at
the 30 end).
Preparation of Circular DNA Template. Phosphorylated linear
ssDNA (91 bases, 500 nM) containing two complementary
sequence regions with a primer ssDNA strand (22 bases) was
annealed to form circular DNA template. Two ssDNA strands
were hybridizedwith an equalmolar ratio by heating at 95 C for
2 min and cooling down to 24 C gradually over 1 h. The nick
between the circular DNA was chemically connected by T4
DNA ligase (1 unit/μL) in the ligase buffer (30 mM Tris-HCl,
pH 7.8, 10 mM MgCl2, 10 mM DTT, 1 mM ATP) followed by
the incubation at 24 C for 4 h.
Synthesis of Antisense DNA Microsponge. To construct antisense
DNA microsponge (ODN-MS), circular DNAs (300 nM) were
mixed with φ29 DNA polymerase (5 units/μL) and deoxyribo-
nucleotide triphosphate (2 mM) in the reaction buffer (40 mM
Tris-HCl (pH 7.5), 50 mM KCl, 10 mM MgCl2, 5 mM (NH4)2SO4,
and 4 mM dithiothreitol), and then allowed to proceed at 24 C
for 24 h for the RCA process. To synthesize the fluorescently
modified ODN-MS, Cyanine 5-UTP was additionally added to
final concentration of 0.5 mM during the RCA reaction. For the
polymeric ODN staining in ODN-MS, ssDNA-specific dye (SYBR II)
was used after particle generation by following the manufac-
turer's instruction. The resultant product was sonicated and
pipetted multiple times until the particle products were well
dispersed. The solutionwas thencentrifugedat 8000 rpm for5min
to collect the ODN-MS product. DNase-free water was used for
additional washing steps to eliminate the reagents of RCA.
Gel Electrophoresis. The molecular weight of polymeric DNAs
and the stability of polymeric DNAs were characterized by gel
electrophoresis. Agarose and TB buffer were mixed to a specific
percent (0.52%) according to a weight of agarose/volume of
buffer ratio (wt/vol). Mixture was heated inmicrowave for 1 min
and then GelRed gel stain was added. The solution was im-
mediately poured into rack and allowed to solidify for 20 min.
The solidified gel in rack was transferred to gel running appa-
ratus that was filled with TB buffer. DNA samples were prepared
with a bromophenol blue containing gel loading dye by
following the manufacturer's protocol (New England Biolabs,
Ipswich, MA) and then loaded into gel. Gel electrophoresis was
conducted at 70 (V/cm) for 6080 (min). Gel images were
visualized using UV transilluminator (Bio-Rad, Hercules, CA).
Measurement of the Polymeric DNA Concentration. Polymeric DNA
structures were prepared by the addition of EDTA (50 mM), a
strong Mg2þ scavenger, because of the disruption of polymeric
DNA/inorganic composite structures of ODN-MS. The concen-
tration of polymeric ssDNA and short ssDNA (ODN control) were
measured according tomanufacturer's instructions for Quant-iT
OliGreen ssDNA Assay Kit (Life Technologies, Carlsbad, CA).
Briefly polymeric DNA or standard solution (10 μL) were mixed
well with Quant-iT OliGreen ssDNA reagent (190 μL) by pipet-
ting. Then the mixtures were placed into a Corning Clear Flat
Bottom 96-wells plate and incubated for 5 min at 24 C.
Fluorescence (λex = 480 nm, λem = 520 nm) was measured
using a fluorescencemicroplate reader (Tecan Infinite 200 PRO).
The concentration of polymeric DNAs was determined by
comparing with an ODN standard curve of fluorescence inten-
sity versus concentration.
Stability Experiments of Polymeric DNA Structures. The DNA stabil-
ity in serum and enzyme was analyzed by measuring the band
intensities of each polymeric DNA/short DNA band in agarose
gel electrophoresis. To perform serum stability test, 150 ng of
polymeric DNA structures and short DNAs were incubated with
50% human serum for 3 days, 2 days, 1 day, 12 h, and 3 h.
Samples were loaded into 2% agarose gel along with untreated
samples of 50, 100, and 150 ng amounts as reference. Gel
electrophoresis was performed at 70 V for 60 min. To perform
DNase stability test, 150 ng polymeric DNA structures and short
DNAs were incubated with DNase (3 units/μL) and reaction
buffer. Samples were incubated for 3 days, 2 days, 1 day, 12 h,
3 h, 2 h, 90 min, 60 min, and 30 min. Samples were loaded into
2% gel along with untreated samples of 50, 100, and 150 ng
amounts as reference. Gel electrophoresis was conducted at
70 V for 60 min. ImageJ densiometry analysis was processed to
calculate the degradation amount (wt %) of polymeric DNA/
short ssDNA.
To perform in vivo pharmacokinetics study, Cy5 dye-labeled
polymeric ssDNA and short ssDNA were prepared. Female NCr
nude mice were treated with Cy5 dye-labeled polymeric ssDNA
or Cy5 labeled short ssDNA. Fluorescence intensity (λex =
640 nm, λem = 700 nm) of dye-labeled DNA was measured from
in vivo imaging systems (Xenogen IVIS Imaging System 200,
Caliper Life Sciences, Hopkinton, MA).
Characterization of ODN-MSs and LbL-ODN-NPs. Scanning electron
microscopy (JEOL JSM-6700F, JSM-6070, and JSM-6060) was
utilized to obtain high-resolution digital images of the ODN-
MSs, condensed nanoparticles, and LbL-ODN-NPs. Samples
were prepared by placing aqueous suspensions onto silicon
wafers. Images were acquired without an additional metal
coating at an accelerating voltage of 2 kV.
Transmission electron microscopy (JEOL 2010 and 2000FX)
was utilized to observe the internal structure of the ODN-MSs
and LbL-ODN-NPs. Images were obtained at an accelerating
voltage of 200 kV.
Fluorescent microscopy (Zeiss AxioSkop 2 MAT) and con-
focal microscopy (Nikon 1AR Spectral Scanning Confocal
Microscope) were used to conﬁrm the presence of polymeric
ssDNA product in the ODN-MSs generated by the RCA. After
particles formation through RCA, the ODN-MSs were stained
with the ssDNA-speciﬁc dye (SYBR II) by following the com-
pany's instruction (Lonza, Walkersville, MD). Green-ﬂuores-
cently stained ODN-MSs were then observed by ﬂuorescent
microscopy. Another DNA visualization method was used by
adding ﬂuorescently labeled deoxyribonucleotide (Cyanine
5-dUTP or Fluorescein) during RCA process. Confocal micro-
scopy was then utilized to visualize the localization of DNA
withinmicrosponges. The progression of condensationwas also
monitored by confocal microscopy. To prepare dual-labeled
ﬂuorescence system for this observation, Fluorescein-12-
dUTP (corresponding to green color) was used to construct
dye-labeled ODN-MSs during RCA synthesis. Cyanine 5.5
(corresponding to red color) conjugated poly-L-lysine (PLL)
(Mw 25000 g/mol) was prepared by following the previously
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polyelectrolyte complexation was observed via confocal micro-
scopy at varied concentrations of dye-PLL.
The elemental composition of the ODN-MS microstructures
and the condensed nanoparticles were investigated in detail
using scanning transmission electron microscopy (JEOL 2010F)
equipped with an analytical scanning imaging device (ASID)
and an INCA energy dispersive X-ray spectroscopy (EDX) de-
tector. Elemental mapping was carried out using a 1 nm probe.
Powder X-ray diﬀraction (PXRD) was used to analyze the
crystalline structure of ODN-MSs and condensed nanoparticles.
Samples for PXRD were prepared by placing aqueous suspen-
sions onto copper (Cu) tapes. Data collection proceeds were
achieved using a Rigaku rotating anode X-ray powder diﬀracto-
meters. PXRD patterns were recorded from 5 to 40 2Θ in a
parallel beam conﬁguration ﬁtted with a 9 kW rotating anode
copper source.
Condensation and Layer-by-Layer Assembly on ODN-MS. The con-
densation process of ODN-MS is properly applied to improve
the delivery efficiency of polymeric DNA. The cationic polymers
including PLL or PEI can be used as polymeric condensing
agents by means of strong ionic interactions with negatively
charged ODN-MS. To find out the optimal conditions for con-
densation, the polymer stock solution (e.g., PLL, Mw 25000 g/
mol, 5.0 mg/mL) was added into the ODN-MS solution at varied
concentrations (0.15 mg/mL). Then the mixtures were gently
mixed for 4 h. Access amount of free polymer in the supernatant
was discarded by following the centrifugation at 12000 rpm for
5 min. The condensed particles were then resuspended in PBS
solution and repeated washing steps twice.
For assembly of the additional layering, the variety of
polymer stock solution such as PEI (Mw 25000 g/mol, 5.0
mg/mL), ssDNA (Mw 8000 g/mol, 5.0 mg/mL), and PEGPGA
(Mw 13000 g/mol, 5.0 mg/mL) were prepared separately. The
condensed particles were mixed with each polymer stock
solution and then allowed 4 h gentle mixing. Access amount
of unreacted free polymer in the supernatant was removed by
following the centrifugation at 12000 rpm for 5 min. The
resultant layered particles were then resuspended in PBS solu-
tion and allowed an additional washing. This layering step could
be repeated until the predeﬁned layering numbers of LbL-ODN-
NPs were achieved.
Characterization of LbL-ODN-NPs. Dynamic Light Scattering (DLS)
and Zeta Potential. The surface charge and size of ODN-MSs
and LbL-ODN-NPs were measured using zeta-potential and
dynamic light scattering (DLS) instruments (Malvern Nano-
ZS90 zetasizer, Westborough, MA). The particles were diluted
in Milli-Q water, and three measurements were performed per
each sample at 24 C.
Intracellular Uptake Study. Cellular uptake of LbL-MS-NPs
and ODN-MS was examined by confocal microscopy and flow
cytometry. SKOV3 cells (1 105 cells) in suspensionmedia were
seeded in CELLview glas bottom dish (Greiner Bio-One GmbH,
Germany) per well and maintained for 24 h. The Cy5.5 fluores-
cently labeled LbL-ODN-NPs or ODN-MSwas added in eachwell
in the presence of DPBS (Life Technologies, Carlsbad, CA) and
then incubated for 3 h at 37 or 4 C. At the end period of
incubation, cells were washed three times with PBS and fixed
with 4% paraformaldehyde. For fluorescence imaging, cells
were permeabilized in 0.1% Triton X100 for 10 min and stained
Alexa Fluor 488-phalloidin (Invitrogen, Carlsbad, California) and
nuclei were stained with DAPI (40,6-diamidino-2-phenylindole).
An antifade reagent (Invitrogen, Carlsbad, California) was added
according to the manufacturer's protocol. Fluorescent images
of the cells were acquired using confocal microscope (Nikon
1AR Spectral Scanning Confocal Microscope, Melville, NY).
The quantity of uptake was obtained by ﬂow cytometry.
SKOV3 cells (2 104 cells) in suspensionmediawere seeded in a
96-well plate and maintained for 24 h. The Cy5.5 ﬂuorescently
labeled LbL-ODN-NPs or ODN-MS (100 μg/mL) was treated in
each well in the presence of DPBS (Life Technologies, Carlsbad,
CA) and then incubated for various periods of times at 37 C. The
cell-associated ﬂuorescence was determined by ﬂow cytometer
(BD LSRFortessa) equipped with a BD high throughput sampler
(HTS) for the 96-well plate format and analyzed by BD FACSDiva
software (BD Biosciences, Franklin Lakes, NJ).
In Vitro Knockdown Experiments and Cell Proliferation Assays.
SKOV3-LUC/SKOV3 cells were used in in vitro knockdown
evaluation and cell proliferation assay. Cells were maintained
in growth media consisting of Minimum Essential Media-Alpha
(MEM-R), 10% fetal bovine serum (FBS), and 1% penicillin
streptomycin. Stable both firefly and renilla luciferase-overex-
pressing SKOV3 cells were prepared using lentivirus vectors
according to the manufacturer's protocols (Cell Biolabs, San
Diego, CA).
For sample preparations, the antisense strand of ﬁreﬂy
luciferase sequences were obtained from Ambion (Austin, TX).
ODN-MSs and LbL-ODN-NPs were prepared as aforementioned
procedures. The samples were diluted in DPBS (Life Technolo-
gies, Carlsbad, CA) to 10 μL ﬁnal volumes for each ODN amount.
The amounts of ODN-MSs and LbL-ODN-NPs were normalized
to the concentration of ODN loading. A single-stranded ODN
control (∼22 bases) with the conventional transfection reagent
(i.e., lipofectamine, Invitrogen, Carlsbad, CA) was used as a
positive control. As suggested by the company, the 1:3 ratio
(w/v) of a single-stranded ODN/lipofectamine (ODN/Lipo) was
used to form liposome. SKOV3 cells (2  104) were seeded in
each well of a 96-wells plate and maintained. After 24 h, the
MEM-R media was replaced with DPBS. The cells were treated
with prepared ODN samples (10 μL) of ODN-MSs, LbL-ODN-NPs,
and ODN/Lipo at varied ODN amounts were treated to the cells
and then gently mixed. The cells were incubated in the con-
trolled-temperature at 37 Cwith 5%CO2 incubator for 4 h. After
4 h of transfection DPBS was replaced with MEM-R. Both
knockdown and cell proliferation evaluations were carried out
after 48 h additional incubation.
For ﬁreﬂy luciferase silencing evaluation, the luciferase
assay was performed using the Dual-Glo Luciferase Assay Kit
(Promega, Madison, WI) as the kit's protocol and luminescence
was measured using a microplate reader (Tecan Inﬁnite 200
PRO). Transfections were conducted in quadruplicate. The level
of ﬁreﬂy luciferase silencing (%) from each samplewas obtained
by comparing the luminescence value from Renilla luciferase.
The cell proliferationwas evaluated using CCK-8 kit (Dojindo
Molecular Technologies, Rockville, MD) following the manufac-
turer's protocols. Brieﬂy, CCK-8 reagent solution (10 μL) was
directly added to the each well of the plate and then the plate
was incubated for 1 h at 37 C. The amount of a water-soluble
formazan (a yellow-colored product) was determined by the
absorbance value at 450 nm using a microplate reader (Tecan
Inﬁnite 200 PRO). The cell proliferation (%) of each sample
was determined using the absorbance value of a prepared
calibration curve that contains given numbers of viable cells
(untreated control).
In Vivo Biodistribution Experiments. Female NCr and BALB/c
nude mice (46 weeks old, Taconic, Hudson, NY) were used
for biodistribution experiments. Mice fed on the alfalfa-free
special diet (AIN-93 MMaintenance Purified Diet from TestDiet)
for a week before and during experimentation to reduce the
body autofluorescence level. All animal care and in vivo experi-
mental procedures were performed following institutionally
approved protocols and regulations (MIT Department of Com-
parative Medicine and NIH Principles of Laboratory Animal
Care).
Biodistribution of LbL-ODN-NPs clearance was investigated
in BALB/c nude mice via intravenous administration (e.g., tail
vein injection). The Cy 5.5-labeled LbL-ODN-NPs suspended in
PBS were administered at the ODN concentration of 1.0 mg/kg
in 0.1 mL injection volume. Whole-animal ﬂuorescence images
are obtained ventrally at the preassigned time points using IVIS
whole-animal imaging system with Living Image software
(Xenogen, Caliper Instruments) to measure the circulation
serum half-life of the control ssDNA, polymeric DNA, and LbL-
ODN-NPs. Imaging and circulation data were captured using
ﬂuorescent overlay (λex = 640 nm, λem = 700 nm) and ﬁtted
with a 2-phase decay model (PRISM) with both slow and fast
half-lives presented. For blood circulation persistence analysis
of LbL-ODN-NPs, the existence of particles in blood was quanti-
ﬁed with the Licor Odyssey system by measuring percent
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Statistical Analysis. All data represent mean values with stan-
dard deviation (SD) from three independent measurements.
Statistical analysis between different treatments was processed
by a Student's t test. Statistical significance was assigned for
p < 0.05 (95% confidence level).
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